A retrospective claims data analysis published in JMCP found that patients with metastatic melanoma treated with PD-1 had substantially lower costs than patients treated with other first line agents.
A retrospective claims data analysis published in JMCP found that patients with metastatic melanoma treated with PD-1 had substantially lower costs than patients treated with other first line agents.